Cargando…
Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide
Women with epilepsy (WWE) wishing for a child represent a highly relevant subgroup of epilepsy patients. The treating epileptologist needs to delineate the epilepsy syndrome and choose the appropriate anti-seizure medication (ASM) considering the main goal of seizure freedom, teratogenic risks, chan...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189531/ https://www.ncbi.nlm.nih.gov/pubmed/35706844 http://dx.doi.org/10.1177/17562864221101687 |
_version_ | 1784725611848138752 |
---|---|
author | Nucera, Bruna Brigo, Francesco Trinka, Eugen Kalss, Gudrun |
author_facet | Nucera, Bruna Brigo, Francesco Trinka, Eugen Kalss, Gudrun |
author_sort | Nucera, Bruna |
collection | PubMed |
description | Women with epilepsy (WWE) wishing for a child represent a highly relevant subgroup of epilepsy patients. The treating epileptologist needs to delineate the epilepsy syndrome and choose the appropriate anti-seizure medication (ASM) considering the main goal of seizure freedom, teratogenic risks, changes in drug metabolism during pregnancy and postpartum, demanding for up-titration during and down-titration after pregnancy. Folic acid or vitamin K supplements and breastfeeding are also discussed in this review. Lamotrigine and levetiracetam have the lowest teratogenic potential. Data on teratogenic risks are also favorable for oxcarbazepine, whereas topiramate tends to have an unfavorable profile. Valproate needs special emphasis. It is most effective in generalized seizures but should be avoided whenever possible due to its teratogenic effects and the negative impact on neuropsychological development of in utero-exposed children. Valproate still has its justification in patients not achieving seizure freedom with other ASMs or if a woman decides to or cannot become pregnant for any reason. When valproate is the most appropriate treatment option, the patient and caregiver must be fully informed of the risks associated with its use during pregnancies. Folate supplementation is recommended to reduce the risk of major congenital malformations. However, there is insufficient information to address the optimal dose and it is unclear whether higher doses offer greater protection. There is currently no general recommendation for a peripartum vitamin K prophylaxis. During pregnancy most ASMs (e.g. lamotrigine, oxcarbazepine, and levetiracetam) need to be increased to compensate for the decline in serum levels; exceptions are valproate and carbamazepine. Postpartum, baseline levels are reached relatively fast, and down-titration is performed empirically. Many ASMs in monotherapy are (moderately) safe for breastfeeding and women should be encouraged to do so. This review provides a practically oriented overview of the complex management of WWE before, during, and after pregnancy. |
format | Online Article Text |
id | pubmed-9189531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-91895312022-06-14 Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide Nucera, Bruna Brigo, Francesco Trinka, Eugen Kalss, Gudrun Ther Adv Neurol Disord Neurological Disorders in Women Women with epilepsy (WWE) wishing for a child represent a highly relevant subgroup of epilepsy patients. The treating epileptologist needs to delineate the epilepsy syndrome and choose the appropriate anti-seizure medication (ASM) considering the main goal of seizure freedom, teratogenic risks, changes in drug metabolism during pregnancy and postpartum, demanding for up-titration during and down-titration after pregnancy. Folic acid or vitamin K supplements and breastfeeding are also discussed in this review. Lamotrigine and levetiracetam have the lowest teratogenic potential. Data on teratogenic risks are also favorable for oxcarbazepine, whereas topiramate tends to have an unfavorable profile. Valproate needs special emphasis. It is most effective in generalized seizures but should be avoided whenever possible due to its teratogenic effects and the negative impact on neuropsychological development of in utero-exposed children. Valproate still has its justification in patients not achieving seizure freedom with other ASMs or if a woman decides to or cannot become pregnant for any reason. When valproate is the most appropriate treatment option, the patient and caregiver must be fully informed of the risks associated with its use during pregnancies. Folate supplementation is recommended to reduce the risk of major congenital malformations. However, there is insufficient information to address the optimal dose and it is unclear whether higher doses offer greater protection. There is currently no general recommendation for a peripartum vitamin K prophylaxis. During pregnancy most ASMs (e.g. lamotrigine, oxcarbazepine, and levetiracetam) need to be increased to compensate for the decline in serum levels; exceptions are valproate and carbamazepine. Postpartum, baseline levels are reached relatively fast, and down-titration is performed empirically. Many ASMs in monotherapy are (moderately) safe for breastfeeding and women should be encouraged to do so. This review provides a practically oriented overview of the complex management of WWE before, during, and after pregnancy. SAGE Publications 2022-06-11 /pmc/articles/PMC9189531/ /pubmed/35706844 http://dx.doi.org/10.1177/17562864221101687 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Neurological Disorders in Women Nucera, Bruna Brigo, Francesco Trinka, Eugen Kalss, Gudrun Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title | Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title_full | Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title_fullStr | Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title_full_unstemmed | Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title_short | Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
title_sort | treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide |
topic | Neurological Disorders in Women |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189531/ https://www.ncbi.nlm.nih.gov/pubmed/35706844 http://dx.doi.org/10.1177/17562864221101687 |
work_keys_str_mv | AT nucerabruna treatmentandcareofwomenwithepilepsybeforeduringandafterpregnancyapracticalguide AT brigofrancesco treatmentandcareofwomenwithepilepsybeforeduringandafterpregnancyapracticalguide AT trinkaeugen treatmentandcareofwomenwithepilepsybeforeduringandafterpregnancyapracticalguide AT kalssgudrun treatmentandcareofwomenwithepilepsybeforeduringandafterpregnancyapracticalguide |